[6-K] Haleon plc American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

On 19 June 2025, Haleon plc (LSE/NYSE: HLN) filed a Form 6-K reporting activity under the share buyback programme launched on 28 March 2025. On 18 June 2025 the company repurchased 1,009,204 ordinary shares of £0.01 each for cancellation.

Key transaction metrics

• Shares purchased: 1,009,204
• Price range: 382.90 p – 386.70 p
• Volume-weighted average price: 384.87 p
• Purpose: Cancellation under authorised Buyback Programme

Post-settlement, registered share capital totals 8,993,584,706 ordinary shares, of which 4,080,205 are held in treasury. The resulting number of ordinary shares with voting rights is 8,989,504,501. Investors should apply this updated figure when assessing FCA disclosure thresholds.

A trade-by-trade schedule, published to comply with Article 5 of the UK Market Abuse Regulation, is available via the London Stock Exchange link provided. The filing reiterates that the announcement is not an offer to sell or solicit securities and supplies contact details for investor and media enquiries.

Positive

• Execution of authorised share buyback signals commitment to shareholder returns
• Cancellation of repurchased shares marginally lowers share count and potential dilution

Negative

• Repurchased shares amount to roughly 0.01% of shares outstanding, limiting near-term financial impact

Insights

Financial Analyst

TL;DR Haleon buys back 1.0 M shares (~0.01% of float); shareholder-friendly but financially immaterial.

The purchase of 1,009,204 shares at a 384.87 p VWAP modestly reduces outstanding voting shares to 8.99 B. While consistent with the March 2025 Buyback Programme, the volume represents only about 0.01 % of the company’s equity, so immediate EPS or valuation impact is negligible. Still, ongoing execution signals management’s commitment to return capital and may set a supportive tone for long-term shareholders.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	19 June 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

19 June 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of the following number of ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under its share buyback programme announced on 28 March 2025 (the "Buyback Programme").

Date of purchase:	18 June 2025
Number of Shares purchased:	1,009,204
Highest price paid per share (p):	386.70
Lowest price paid per share (p):	382.90
Volume weighted average price paid per share (p):	384.87

Following the settlement of the above, the Company's registered share capital is 8,993,584,706 ordinary shares of £0.01 each, of which 4,080,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,989,504,501 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/4721N_1-2025-6-18.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries

Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Emma White	+44 7823 523562
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: June 19, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

How many Haleon (HLN) shares were repurchased on 18 June 2025?

1,009,204 ordinary shares were bought for cancellation under the buyback programme.

What was the average price paid per HLN share during the buyback?

The volume-weighted average price was 384.87 pence per share.

How many Haleon voting shares are outstanding after the transaction?

The updated figure is 8,989,504,501 ordinary shares with voting rights.

When did Haleon announce its current share buyback programme?

The buyback programme was announced on 28 March 2025.

Where can investors find the detailed trade breakdown for the buyback?

A full schedule is available at the linked London Stock Exchange PDF: rns-pdf.londonstockexchange.com/rns/4721N_1-2025-6-18.pdf.